These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 31227501)

  • 21. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
    Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
    Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
    Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L
    Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.
    Troiano G; Caponio VCA; Zhurakivska K; Arena C; Pannone G; Mascitti M; Santarelli A; Lo Muzio L
    Cell Prolif; 2019 Mar; 52(2):e12537. PubMed ID: 30443950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.
    Wang C; Zhu H; Zhou Y; Mao F; Lin Y; Pan B; Zhang X; Xu Q; Huang X; Sun Q
    Breast J; 2017 Jul; 23(4):436-443. PubMed ID: 28079291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
    Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
    Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.
    Zhou ZQ; Zhao JJ; Pan QZ; Chen CL; Liu Y; Tang Y; Zhu Q; Weng DS; Xia JC
    J Immunother Cancer; 2019 Aug; 7(1):228. PubMed ID: 31455411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis.
    Xue S; Song G; Yu J
    Sci Rep; 2017 Jun; 7(1):4231. PubMed ID: 28652622
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
    Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J
    Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
    Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
    Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis.
    Lei C; Peng X; Gong X; Fan Y; Wu S; Liu N; Li L; Huang J; Zheng G; Long Z
    Aging (Albany NY); 2019 Dec; 11(24):12568-12580. PubMed ID: 31881008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.
    Iacovelli R; Nolè F; Verri E; Renne G; Paglino C; Santoni M; Cossu Rocca M; Giglione P; Aurilio G; Cullurà D; Cascinu S; Porta C
    Target Oncol; 2016 Apr; 11(2):143-8. PubMed ID: 26429561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer.
    Zhai Q; Fan J; Lin Q; Liu X; Li J; Hong R; Wang S
    PLoS One; 2019; 14(10):e0223325. PubMed ID: 31584964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PD-L1 expression is increased in a subset of basal type breast cancer cells.
    Soliman H; Khalil F; Antonia S
    PLoS One; 2014; 9(2):e88557. PubMed ID: 24551119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
    Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.
    Zhang M; Dong Y; Liu H; Wang Y; Zhao S; Xuan Q; Wang Y; Zhang Q
    Sci Rep; 2016 Nov; 6():37933. PubMed ID: 27892511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 Expression in Patients with Non-Medullary Thyroid Cancer: A Systematic Review and Meta-Analysis.
    Aghajani M; Graham S; McCafferty C; Shaheed CA; Roberts T; DeSouza P; Yang T; Niles N
    Thyroid; 2018 Mar; 28(3):349-361. PubMed ID: 29455638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
    Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
    Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
    Wen Y; Chen Y; Duan X; Zhu W; Cai C; Deng T; Zeng G
    Clin Exp Med; 2019 Nov; 19(4):407-416. PubMed ID: 31407099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.